Semaglutide is a GLP-1 receptor agonist, a medicine that copies the action of your own GLP-1 hormone, as described in the National Library of Medicine clinical reference on semaglutide
Each peptide carries default vial sizes, dose ranges, and notes on the correct diluent to reduce injection site reactions
NICE obesity guidance recommends evidence-based interventions including dietary change, physical activity, and licensed medications such as orlistat or semaglutide
whilst this has not been established as a formal contraindication in UK SmPCs for approved GLP-1 receptor agonists, clinical caution and specialist review are warranted for individuals with relevant thyroid or endocrine history [24] [25] Pancreatitis (current or historical), as GLP-1-based therapies have been associated with pancreatic inflammation [19] Type 1 or Type 2 diabetes , particularly if already managed with insulin, sulfonylureas, or other glucose-lowering agents, due to an increased risk of hypoglycaemia Cardiovascular disease , given observed increases in heart rate with retatrutide in trial data Renal or hepatic impairment , as these may affect drug metabolism and tolerability Pregnancy or breastfeeding , as safety data in these populations are entirely absent When to seek urgent medical attention: If, after administration, an individual experiences severe nausea or vomiting, chest pain, rapid or irregular heartbeat, severe abdominal pain, signs of an allergic reaction (such as rash, swelling of the face or throat, or difficulty breathing), or symptoms of hypoglycaemia (such as sweating, shaking, confusion, or loss of consciousness) , they should: Call 999 immediately for life-threatening emergencies Call NHS 111 for urgent medical advice Attend an A&E department as appropriate Transparency with healthcare professionals about the substance used is essential for safe and effective clinical management
CJC-1295 (No DAC) / Ipamorelin is a research blend consisting of two structurally defined synthetic peptides produced through controlled peptide synthesis
TB-500 is the much shorter N-acetylated fragment Ac-LKKTETQ, corresponding to residues 17 to 23 of thymosin beta-4
